Orexo AB (ORX):企業の財務・戦略的SWOT分析

◆英語タイトル:Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1169
◆発行会社(調査会社):GlobalData
◆発行日:2020年3月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Orexo AB (ORX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Orexo AB (Orexo) is a specialty pharmaceutical company that focuses on the research, formulation, development, registration and commercialization of drugs. The company’s commercial product portfolio consists of Abstral, Edluar and Zubsolv. The company employs proprietary drug delivery technologies in the development of its products. It also carries out the industrial-scale production of pharmaceutical products. Orexo collaborates with various pharmaceutical companies to advance and commercialize its products. Orexo is headquartered in Uppsala, Sweden.

Orexo AB Key Recent Developments

Jan 30,2020: Q4 incl full year report 2019
Dec 02,2019: Orexo appoints Dennis Urbaniak as Executive Vice President digital health
Nov 28,2019: Orexo acquires US rights to commercialise vorvida
Oct 24,2019: Orexo interim report Q3 2019
Aug 21,2019: Orexo and GAIA partner on digital therapy for opioid use disorder

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Orexo AB – Key Facts
Orexo AB – Key Employees
Orexo AB – Key Employee Biographies
Orexo AB – Major Products and Services
Orexo AB – History
Orexo AB – Company Statement
Orexo AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Orexo AB – Business Description
Product Category: Abstral
Overview
Performance
Product Category: Edluar
Overview
Performance
Product Category: OX-MPI
Overview
Performance
Product Category: Zubsolv
Overview
Performance
Geographical Segment: EU
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: US
Performance
R&D Overview
Orexo AB – SWOT Analysis
SWOT Analysis – Overview
Orexo AB – Strengths
Orexo AB – Weaknesses
Orexo AB – Opportunities
Orexo AB – Threats
Orexo AB – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Orexo AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jan 30, 2020: Q4 incl full year report 2019
Dec 02, 2019: Orexo appoints Dennis Urbaniak as Executive Vice President digital health
Nov 28, 2019: Orexo acquires US rights to commercialise vorvida
Oct 24, 2019: Orexo interim report Q3 2019
Aug 21, 2019: Orexo and GAIA partner on digital therapy for opioid use disorder
Jul 11, 2019: Orexo interim report Q2 2019
Jul 09, 2019: Orexo prepays part of the corporate bond loan
May 02, 2019: Orexo: Interim report Q1 2019
Jan 30, 2019: Orexo: Q4 incl. full year report 2018
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Orexo AB, Key Facts
Orexo AB, Key Employees
Orexo AB, Key Employee Biographies
Orexo AB, Major Products and Services
Orexo AB, History
Orexo AB, Subsidiaries
Orexo AB, Key Competitors
Orexo AB, Ratios based on current share price
Orexo AB, Annual Ratios
Orexo AB, Annual Ratios (Cont...1)
Orexo AB, Annual Ratios (Cont...2)
Orexo AB, Interim Ratios
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Orexo AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Orexo AB, Performance Chart (2015 - 2019)
Orexo AB, Ratio Charts
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Orexo AB, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Orexo AB (ORX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Exact Sciences Corp (EXAS):企業の財務・戦略的SWOT分析
    Exact Sciences Corp (EXAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Nando’s Chickenland Limited:企業の戦略的SWOT分析
    Nando's Chickenland Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Revance Therapeutics Inc (RVNC):製薬・医療:M&Aディール及び事業提携情報
    Summary Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The company’s product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of glabellar lines, cervical dystonia, and plantar fas …
  • Enel Generacion Chile SA:企業の発電所・SWOT分析2018
    Enel Generacion Chile SA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Brake Bros Limited:企業の戦略的SWOT分析
    Brake Bros Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Dataprep Holdings Bhd (DATAPRP):企業の財務・戦略的SWOT分析
    Dataprep Holdings Bhd (DATAPRP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Transcatheter Technologies GmbH-医療機器分野:企業M&A・提携分析
    Summary Transcatheter Technologies GmbH (Transcatheter) is a medical equipment company that develops aortic valve implantation system. The company develops technologies for self-expanding valve prostheses and endovascular stents through inner catheters. It develops aortic valve implantation system f …
  • Applied Industrial Technologies, Inc.:戦略・SWOT・企業財務分析
    Applied Industrial Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Applied Industrial Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Laissez-Faire Catering Pty Ltd
    Laissez-Faire Catering Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Laissez-Faire Catering Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Alibaba Group Holding Limited:企業のM&A・事業提携・投資動向
    Alibaba Group Holding Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Alibaba Group Holding Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Cara Therapeutics Inc (CARA):医療機器:M&Aディール及び事業提携情報
    Summary Cara Therapeutics Inc (Cara Therapeutics) is a biotechnology company that develops and commercializes chemical entities for acutepain, chronic pain and pruritus. The company offers kappa opioid receptor agonists in the therapeutic areas of acute pain, chronic pain, neuropathic pain and pruri …
  • Oversea-Chinese Banking Corp Ltd:企業の戦略・SWOT・財務情報
    Oversea-Chinese Banking Corp Ltd - Strategy, SWOT and Corporate Finance Report Summary Oversea-Chinese Banking Corp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Entasis Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Entasis Therapeutics Inc (Entasis) is a drug development company that discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, ETX0282, ETX0914 and Zoliflodacin. Its ETX2514 is a potent inhibitor of class A, C, …
  • ABB Ltd (ABBN)-エネルギー分野:企業M&A・提携分析
    Summary ABB Ltd. (ABB) is a provider of power and automation technologies. The company provides solutions for secure, energy-efficient generation, transmission and distribution of electricity and for increasing productivity in industrial, commercial and utility operations. ABB’s product and service …
  • Progenitor Cell Therapy LLC-製薬・医療分野:企業M&A・提携分析
    Summary Progenitor Cell Therapy LLC (PCT), a subsidiary of Caladrius Biosciences Inc is an external development and manufacturing company that offers cell therapy products. The company offers services that include cell and tissue processing; storage, distribution and delivery; consulting and regulat …
  • PNM Resources, Inc. (PNM)-エネルギー分野:企業M&A・提携分析
    Summary PNM Resources, Inc. (PNMR) is an investor-owned holding company that provides electricity and electric services in New Mexico and Texas. It has interests in PNM and TNMP utilities. PNM produces electricity from coal, natural gas, nuclear, solar, wind, and geothermal sources; transmits and di …
  • BNRG Renewables Ltd:電力:M&Aディール及び事業提携情報
    Summary BNRG Renewables Ltd (BNRG) is a renewable energy company that develops, finance and constructs ground mounted and rooftop solar photovoltaic projects. The company offers services such as project management, site assessment, planning and grid connection, asset management, and construction man …
  • Titan Pharmaceuticals Inc (TTNP):企業の財務・戦略的SWOT分析
    Summary Titan Pharmaceuticals Inc (Titan) is a pharmaceutical company that develops therapeutics for the treatment of serious medical disorders. The company develops drugs using ProNeura, a proprietary drug delivery platform, for the treatment of chronic diseases. It product portfolio provides probu …
  • Semperit AG Holding (SEM):企業の財務・戦略的SWOT分析
    Summary Semperit AG Holding (Semperit) is a developer, manufacturer and marketer of rubber products for the medical and industrial sectors. The company’s products include surgical gloves, examination gloves, disposable protective gloves and reusable protective gloves. It also offers hydraulic hoses, …
  • Acarix AS-医療機器分野:企業M&A・提携分析
    Summary Acarix A/S (Acarix) is a medical device company that offers design and development of non-invasive cardiac screening products. The company offers non-invasive screening device, CADScor system used to record, process and display heart signals as a patient specific score as the CAD-score on th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆